Home / Locations / Nice, Alpes-Maritimes
59 recruiting in this snapshot
These studies list at least one location in Nice, Alpes-Maritimes. A listed city is not a guarantee the site is still taking patients — call the contact.
This study wants to measure the long-term safety and how well it works of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase.
NCT03486873 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
This is a multicenter randomly assigned controlled clinical trial with an adaptive design assessing the how well it works of setting the ventilator based on measurements of respiratory mechanics (recruitability and effort) to reduce Day 60 mortality in patients with acute respiratory distress syndrome (ARDS). The CAVIARDS study is also a basket trial; a basket trial design examines a single intervention in multiple disease populations.
NCT03963622 · Official ClinicalTrials.gov record · Unity Health Toronto
The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.
NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The main objective of the study is to assess how well it works and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, neither you nor the study doctors know who gets the real treatment, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO.
NCT05263206 · Official ClinicalTrials.gov record · Sanofi
The goal of this randomly assigned clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the % of patients without disease activity at 2 years.
NCT05758831 · Official ClinicalTrials.gov record · Rennes University Hospital
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as this drug alone in participants with advanced solid tumors.
NCT05768139 · Official ClinicalTrials.gov record · Eli Lilly and Company
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy. The optimal intervention in patients with secondary loss-of-response (LOR) is still poorly defined, as there are still scant data on how best to choose the next intervention from among dose-intensification, switch to another anti-TNF or switch out of the anti-TNF class.
NCT06180382 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Saint Etienne
This is a multi-center evaluation of efruxifermin (EFX) in a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
NCT06215716 · Official ClinicalTrials.gov record · Akero Therapeutics, Inc
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. this study wants to measure the how well it works and safety of TAK-279 versus dummy treatment (placebo) in participants with moderately to severely active Crohn's disease (CD).
NCT06233461 · Official ClinicalTrials.gov record · Takeda
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
The study will assess the how well it works and safety of 2 dose regimens of pegozafermin compared to dummy treatment (placebo) for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
NCT06318169 · Official ClinicalTrials.gov record · Hoffmann-La Roche
This is a study evaluating the how well it works and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to dummy treatment (placebo) plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
NCT06345729 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
The study will assess the how well it works and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
NCT06419374 · Official ClinicalTrials.gov record · Hoffmann-La Roche
The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs.
NCT06499285 · Official ClinicalTrials.gov record · Takeda
This is a multi-center evaluation of efruxifermin (EFX) in a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in subjects with compensated cirrhosis due to NASH/MASH.
NCT06528314 · Official ClinicalTrials.gov record · Akero Therapeutics, Inc
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).
NCT06541704 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
NCT06548542 · Official ClinicalTrials.gov record · AbbVie
This study wants to measure the safety and how well it works of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
NCT06585787 · Official ClinicalTrials.gov record · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
This study wants to measure the safety, tolerability, drug levels, and preliminary how well it works of BMS-986507 combinations in adult participants with advanced solid tumors.
NCT06618287 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
This study wants to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers.
NCT06624670 · Official ClinicalTrials.gov record · LEO Pharma
This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. this study wants to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.
NCT06632444 · Official ClinicalTrials.gov record · Boehringer Ingelheim
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * body-mass index (BMI) of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.
NCT06632457 · Official ClinicalTrials.gov record · Boehringer Ingelheim
This study wants to establish the recommended doses and further measure the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
NCT06641908 · Official ClinicalTrials.gov record · EMD Serono Research & Development Institute, Inc.
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC).
NCT06651281 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
The study will measure the physical impact of MS from participant's perspective, provide continued access to ocrelizumab and assess the whether it is safe and how hard side effects are to live with of ocrelizumab. From Protocol Version 6 onwards, treatment within this study will be limited to the currently approved doses of ocrelizumab, 600 milligrams (mg), intravenous (IV) infusion or 920 mg, subcutaneous (SC) injection.
NCT06675955 · Official ClinicalTrials.gov record · Hoffmann-La Roche
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the how well it works of trastuzumab deruxtecan in terms of progression-free survival (PFS).
NCT06680596 · Official ClinicalTrials.gov record · UNICANCER
This study wants to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
NCT06717347 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
International, Multicenter, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment and Event-driven study to assess how well it works, whether it is safe and how hard side effects are to live with of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
NCT06742723 · Official ClinicalTrials.gov record · AstraZeneca
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
NCT06764693 · Official ClinicalTrials.gov record · AbbVie
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomly assigned, multicentre, open-label phase III study
NCT06840782 · Official ClinicalTrials.gov record · Gustave Roussy, Cancer Campus, Grand Paris
The purpose of this Phase 3b study is to assess the how well it works, whether it is safe and how hard side effects are to live with of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
NCT06846281 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
NCT06865105 · Official ClinicalTrials.gov record · AbbVie
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive).
NCT06901531 · Official ClinicalTrials.gov record · Astellas Pharma Global Development, Inc.
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to measure the long-term whether it is safe and how hard side effects are to live with of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
NCT06929273 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and dummy treatment (placebo), leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
NCT06937086 · Official ClinicalTrials.gov record · Eli Lilly and Company
The main purpose of this study is to measure the how well it works and safety of mirikizumab and dummy treatment (placebo) compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
NCT06937099 · Official ClinicalTrials.gov record · Eli Lilly and Company
This is a phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the how well it works of different doses of SAR442970 compared with dummy treatment (placebo) in participants with moderate to severe Crohn's disease.
NCT06958536 · Official ClinicalTrials.gov record · Sanofi
DESTINY-Endometrial01 will investigate the how well it works of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
NCT06989112 · Official ClinicalTrials.gov record · AstraZeneca
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. this study wants to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).
NCT07007065 · Official ClinicalTrials.gov record · AbbVie
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
NCT07064473 · Official ClinicalTrials.gov record · Boehringer Ingelheim
This Phase 3 study is evaluating the safety and how well it works of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD). Enrollment in the primary global cohort has been completed; Study centers in Japan remain open for enrollment for the Japan cohort.
NCT07064759 · Official ClinicalTrials.gov record · 4D Molecular Therapeutics
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
NCT07074418 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Nice
The main purpose of this study is to demonstrate the how well it works and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or dummy treatment (placebo) for 24 weeks (6 months).
NCT07091630 · Official ClinicalTrials.gov record · argenx
A study to measure the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
NCT07116967 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
This study wants to measure the how well it works and safety of added on top of your current treatment KarXT for the treatment of mania in participants with Bipolar-I Disorder.
NCT07140913 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.
NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company
This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.
NCT07174310 · Official ClinicalTrials.gov record · Hoffmann-La Roche
This study wants to evaluate how-well icotrokinra works (clinical how well it works) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
NCT07196722 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
A randomly assigned, Active-Controlled, neither you nor the study doctors know who gets the real treatment, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
NCT07228832 · Official ClinicalTrials.gov record · Summit Therapeutics
This study wants to measure cardiovascular outcomes with orforglipron compared with dummy treatment (placebo) in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
NCT07241390 · Official ClinicalTrials.gov record · Eli Lilly and Company
Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2/FLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response.
NCT07292480 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Nīmes
The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine.
NCT07322003 · Official ClinicalTrials.gov record · Prilenia
This study wants to assess the how well it works and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with dummy treatment (placebo) for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
NCT07351058 · Official ClinicalTrials.gov record · Hoffmann-La Roche
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
NCT07489495 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
This study wants to assess the how well it works and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
NCT07555938 · Official ClinicalTrials.gov record · Hoffmann-La Roche
This study wants to assess how well JNJ-78934804 works (how well it works) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
NCT07577843 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
This study wants to assess how well JNJ-78934804 works (how well it works) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
NCT07577856 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC